Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5397_Библиотеки_им_академика_М_И_Перельмана
.pdf
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
patient classication techniques. This paves the way for more targeted and efcient
clinical trial designs (Sarker 2022).
AI also makes it possible for researchers to construct adaptive trials that can
dynamically change based on real-time data, giving them the information they need
to make informed judgements and modications as the trial goes on (MalandrakiMiller and Riley 2021). This adaptability ensures that the study keeps up to date
with the quickly evolving area of medicine and increases the trial’s sensitivity to
new discoveries. Last but not least, applying AI to enhance clinical trial design
expedites the drug development process and raises the likelihood of discovering
effective medicines for specic patient populations (Fitzgerald etal. 2021).
In an effort to improve clinical trial design, AI’s sophisticated algorithms consider genetic variants in addition to patient demographics and treatment outcomes.
By evaluating genetic data, AI can identify biomarkers that may serve as indicators
of treatment response, enabling the development of more precise and individualised
solutions (Liu etal. 2020). This personalised medicine approach brings in a new era
of targeted therapy and increases the efcacy of clinical trials by tailoring medications to the unique genetic prole of each participant.
AI also makes it easier to incorporate empirical data into clinical trial design.
The integration of data from wearables, patient-reported outcomes, and electronic
health records facilitates a more comprehensive understanding of a medication’s
performance in real-world scenarios. This all-encompassing approach ensures that
clinical trials are not only rigorous but also reective of the various healthcare settings in which medications will be utilised, which improves the generalisability of
study ndings (Majeed and Hwang 2021).
423
19.3.2 Enhanced Patient Acquisition
Patient recruitment is an essential part of clinical trials, and using traditional methods to
identify and enrol suitable patients can be challenging. AI breaks down this barrier with
data-driven strategies to enhance patient acquisition (Locke etal. 2021). Natural language processing (NLP) algorithms are able to search through a vast amount of patient
data, electronic health records, and medical literature in order to identify potential volunteers who meet the rigorous criteria for a particular study (Venugopal 2019).
Furthermore, AI can assist in selecting suitable sites for clinical trials by looking at
demographic and geographic data. This makes the trial’s participant pool more diverse
and representative, which improves the ndings’ generalisability. Articial intelligence (AI) streamlines the patient recruitment process, which not only helps clinical
trials start more smoothly but also increases their validity and overall success.
In the area of better patient acquisition, AI locates potential participants and
facilitates patient involvement. Chatbots and virtual assistants driven by articial
intelligence (AI) can provide information on trials, assist with inquiries, and answer
questions, encouraging a more patient-centric approach. Apart from improving participant understanding and adherence, this engagement raises the public’s positive
perception of clinical trials (Qi etal. 2021).
424
https://t.me/med1917
Another part of patient recruitment that AI helps with is optimising the diversity of
trial participants. Machine learning algorithms can identify variations in participant
demographics and suggest targeted remedies to ensure equitable representation. This
commitment to diversity is both ethically sound and enhances the trial results’ generalisability to different demographic groups (Woodman and Mangoni 2023).
R. Debnath et al.
19.3.3 Forecasting Patient Reactions toBoost Trial
Success Rates
One of AI’s analytical capabilities, predicting patient responses to experimental
medicines, is crucial to the success of clinical trials. Utilising machine learning
algorithms to analyse historical data and identify patterns in patient responses, it is
feasible to develop prediction models that forecast potential responses from different patient cohorts to novel medications (Naveed 2023).
This forecasting power allows researchers to tailor inclusion criteria, stratify
patient groups, and adjust dosages based on expected responses. By incorporating
AI-driven predictive analytics into trial design, researchers can increase patient
safety, decrease the likelihood of unfavourable outcomes, and increase the overall
success rates of clinical trials. This proactive approach not only safeguards participants but also upholds the ethical conduct of clinical research (de Thé etal. 2023).
In the area of patient reaction forecasting, AI not only anticipates therapy
response but also recognises patients who might not respond to treatment. By nding minute patterns in treatment outcome data that indicate positive reactions, articial intelligence (AI) can assist in selecting subgroups that stand to gain the most
from experimental medicine. Focusing resources on patient populations who are
more likely to respond favourably enhances the effectiveness of clinical studies and
ultimately raises success rates.
Furthermore, virtual patient cohorts created by AI-powered simulations enable
researchers to test various hypotheses and enhance trial designs before beginning
actual research. This virtual testing reduces the likelihood of unforeseen problems
and contributes to the development of more robust trial designs (Bates etal. 2020).
Because AI can anticipate patient reactions, researchers may make data-driven decisions and adopt a more exible and adaptive approach to the dynamic eld of clinical research.
19.3.4 Reducing theTime andExpense ofDrug Development
Clinical trials have beneted greatly from articial intelligence’s reduction in the
time and expense associated with drug development. Data analysis and protocol
development are two of the many process phases that AI streamlines, leading to
more efcient and cost-effective trials.
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
By utilising predictive modelling to assist in identifying potential roadblocks and
impediments in the drug development pipeline, articial intelligence (AI) helps researchers proactively address issues that could delay trials. Real-time patient data monitoring
enables prompt identication of unanticipated trends or undesirable events, hence minimising disruptions and facilitating appropriate actions (Majeed and Hwang 2021).
Additionally, AI-driven automation of data extraction and analysis speeds up the
process of generating insights from clinical trial data (Benzidia etal. 2021). By
reducing the need for manual data processing and speeding up decision-making,
this reduces the likelihood of human error. The ultimate result is a more streamlined
and cost-effective drug development process that expedites the release of innovative
treatments into the healthcare sector.
AI contributes to the improvement of supply chain logistics in the endeavour to
reduce the time and expenses related to medication development (Alanazi 2023).
Predictive algorithms have the ability to forecast and accelerate trial-related material needs and procurement process optimisation, leading to efcient resource allocation. Effective supply chain management helps to minimise costs and minimise
delays during the entire drug development process.
Moreover, AI affects data analysis in a way that extends beyond the trial phase
and involves the use of post-trial data. Researchers can continue to obtain meaningful knowledge from completed studies that will assist in the design of post- marketing
surveillance and treatment guidelines in the future by utilising AI to assess longterm follow-up data. This ongoing analysis helps to improve treatment regimens on
an ongoing basis and ensures that the full value of clinical trial data is realised
beyond the rst study period (Xu etal. 2021).
In conclusion, articial intelligence can benet clinical trials in many ways, such
as improved trial design, improved patient acquisition, the capacity to forecast
patient reactions, and a reduction in the time and expense involved in drug development. As technology advances, combining AI with clinical trials could hasten medication development and usher in a new era of patient-centric, data-driven healthcare
innovation.
425
19.4 How AI Is Revolutionising theSearch
forandDevelopment ofDrugs
19.4.1 Integration ofAI Technologies withDomain Expertise
The pharmaceutical business is experiencing a paradigm shift as a result of the revolutionary advancement of drug discovery and development through the integration of
articial intelligence (AI) technologies with domain expertise. Through this synergy,
which combines data-driven insights with specialised knowledge, the computational
power of AI and the sophisticated comprehension provided by domain specialists are
harnessed to speed and optimise the drug discovery process (Zhu 2020):
426
https://t.me/med1917
R. Debnath et al.
• Driven by Data in Drug Discovery: AI in Data Analysis: AI, especially deep
learning and machine learning, is very good at analysing large, complicated data-
sets. In the eld of drug discovery, where an abundance of biological and chemi-
cal data might be difcult, this is very helpful (Bonate etal. 2023).
• Integration of Domain Expertise: Domain specialists provide their in-depth
knowledge of biological systems, pharmacology, and disease causes. This knowl-
edge aids in the development of algorithms and models, guaranteeing the bio-
logical relevance of AI-driven investigations (Vamathevan etal. 2019).
• Identication and Validation of the Target: AI Algorithms: By examining bio-
logical data, machine learning algorithms are able to forecast possible therapeu-
tic targets. These algorithms nd proteins or genes linked to particular diseases
by learning from a variety of datasets, such as proteomics and genomics data.
• Expert Interpretation: When it comes to evaluating predictions produced by AI,
domain specialists are essential. Their expertise aids in verifying if the antici-
pated targets coincide with our understanding of the disease’s underlying bio-
logical mechanisms (Brown etal. 2020).
• Drug Development and Enhancement: Articial Intelligence in Molecular
Design: Deep learning in particular helps in molecular design by forecasting
potential interactions between various chemicals and target proteins. This expe-
dites the process of identifying possible therapeutic candidates.
• Domain Expert Input: Taking into account variables such as toxicity, formula-
tion, and bioavailability, domain experts offer valuable insights into the practical
elements of medication design. By doing this, candidates produced by AI are
guaranteed to meet actual pharmaceutical needs (Saeed and El Naqa 2022).
• Increasing the Effectiveness of Clinical Trials: AI for Patient Stratication: To
nd subpopulations that might react better to particular therapies, machine learn-
ing algorithms examine patient data. This aids in the creation of more focused
and effective clinical trials (Al-Taie etal. 2021).
• Clinical Expertise: Domain experts work together with researchers to develop
clinical trials, taking into account patient safety, trial endpoints, and ethical
issues. Their knowledge guarantees that AI suggestions are consistent with the
requirements of clinical research.
• Repurposing Drugs: AI Data Analysis: AI systems are able to examine current
datasets in order to nd possible new applications for currently approved medi-
cations. This technique is referred to as drug repurposing (Ashri 2019).
• Assessment by Domain Experts: Candidates for repurposing are assessed for
safety and viability by domain experts. Their knowledge is essential for identify-
ing possible hazards and advantages and for directing the formulation of
new drugs.
• AI-Powered Networks and Partnerships:
– Integrated Platforms: To deliver comprehensive solutions, AI-driven drug dis-
covery platforms combine deep learning, machine learning, and domainspecic expertise.
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
– Interdisciplinary Collaboration: A comprehensive strategy is fostered through
collaboration between domain experts, data scientists, and AI experts.
Multidisciplinary teams are better equipped to handle the challenges of drug
discovery (Alowais etal. 2023).
The combination of domain knowledge and AI technologies is revolutionising
the drug discovery process. AI’s computing power and domain specialists’ subtle
insights work together to make the process more focused and efcient, based on a
thorough understanding of biological processes. This cooperative strategy might
shorten the timeframes for medication discovery while also raising the chances of
successfully introducing new and efcient medicines to the market.
427
19.4.2 Quicker Progress oftheTreatment
Articial intelligence (AI) is revolutionising the search and development of medications, and one signicant result of this is the acceleration of treatment development.
The pharmaceutical sector is undergoing a transformation as a result of articial
intelligence (AI) technologies, which have the capacity to handle enormous datasets
and produce insights at an unprecedented velocity (Ahmed etal. 2020). Articial
intelligence speeds up the process of identifying possible drug targets in the search
for better treatments. In order to forecast targets for additional study, machine learning systems quickly analyse complicated biological data. Drug development’s initial phase is considerably shortened by this quick target selection, setting the stage
for quicker advancement. Another area seeing rapid progress is AI-driven medication design. This simplies the design process by using deep learning models to
predict how different chemicals would interact with target proteins (Jiang n.d.).
Drug candidates are optimised more quickly, which decreases the need for laborious iterations and raises the possibility of quickly discovering effective treatment
solutions. The faster pace of therapeutic development is further aided by
AI-facilitated virtual screening and medication repurposing. Large chemical libraries are quickly processed through machine learning methods, which help nd possible candidates for new indications. This method not only saves time but also
makes the most of already-approved medications by perhaps repurposing them for
other medical purposes. Articial intelligence’s analytical powers are applied to
clinical trials to improve trial design. Machine learning nds distinct patient subpopulations for targeted interventions and optimises trial parameters by analysing a
variety of datasets. Clinical trials are conducted more efciently with this strategy,
which facilitates faster data production and decision-making (Serov and
Vinogradov 2022).
AI helps uncover biomarkers rapidly by analysing a variety of omics data, which is
a critical step in customising medicines. Quickly identifying the biomarkers linked to
diseases opens the door to more individualised and efcient treatment plans. The precision medicine age is one where this acceleration is very signicant. Early disease
428
https://t.me/med1917
identication and intervention are aided by the inclusion of AI-powered diagnostics.
The prompt modication of treatment procedures, which guarantees timely interventions and may enhance patient outcomes, is made possible by real- time patient data
monitoring. Articial intelligence (AI) systems’ capacity for continuous learning
improves treatment plans by promoting exible methods derived from continuing
data analysis. AI additionally makes it easier for researchers, doctors, and data scientists to collaborate across disciplines. With the help of this cooperative ecosystem,
data sharing is accelerated, resulting in more effective research methods and a group
effort to comprehend diseases and create focused remedies more quickly (Jiang n.d.).
Conclusively, the transformative inuence of articial intelligence on drug discovery and development results in a more rapid progression from preliminary investigations to the delivery of efcacious therapies. AI substantially accelerates the
development of new treatments by speeding up target identication, drug design,
clinical trials, and biomarker discovery. The healthcare industry could be drastically
altered by this paradigm shift, which promises to give more individualised and
quicker answers (Mbatha etal. 2023).
R. Debnath et al.
19.4.3 Better Results forPatients
A new age of better outcomes for patients has been brought about by articial intelligence’s (AI) revolutionary impact on drug discovery and development. Articial
intelligence is making therapies more individualised and effective by processing
enormous volumes of data, spotting trends, and optimising different phases of drug
discovery and development. AI is helping patients have better outcomes in the following ways (Lipinski etal. 2019):
• Strategies for Targeted Treatment: Machine learning algorithms are used in tar-
get identication to more accurately anticipate possible drug targets by analysing
a variety of biological data.
• Results That Are Focused on the Patient: Targeted identication makes it possi-
ble to create medications that are unique to certain molecular pathways, improv-
ing the chances of success and reducing side effects.
• Design and Optimisation of Drugs:
– Deep Learning Models: AI-powered models calculate the interactions between
various chemicals and target proteins, accelerating the development of
new drugs.
– Optimised Formulations: Patients can receive novel therapies sooner thanks
to shorter development times caused by speedier drug design and optimisation (Jyothi n.d.).
• Enhanced Customisation Using Biomarkers:
– AI in Biomarker Discovery: Machine learning examines omics data to nd
disease-related biomarkers.
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
– Tailored Therapies: Quick biomarker identication enables more individual-
ised therapy plans, guaranteeing that therapies are in line with unique patient
traits and illness proles (Schwager etal. 2021).
• Effective Clinical Trial Architecture:
AI helps to improve the design of clinical trials by identifying patient subpopulations that are more likely to respond favourably.
– Faster Clinical Validation: Effective trial designs expedite the validation of drug
candidates, enabling patients to receive potentially benecial treatments more
quickly.
• Early Identication and Management of Diseases:
– AI-Powered Diagnostics: To diagnose diseases early, AI apps examine
patient data.
– Better Results: By addressing diseases at earlier, more manageable stages,
early diagnosis allows for prompt therapies that may improve patient
outcomes.
• Adaptive Approaches to Therapy:
AI systems acquire knowledge through continuous learning from real-world data
and ongoing clinical trials. By optimising therapies based on the most recent insights
and patient responses, this ongoing learning enables adaptable treatment techniques
(Greene etal. 2010).
429
• Reduced Adverse Reactions and Safety Issues:
– Real-Time Monitoring: AI systems keep an eye on patient data in real time,
which makes it easier to quickly identify negative consequences.
– Patient Safety: Early detection of safety issues guarantees that patients receive
care that has the fewest possible hazards, improving overall safety and wellbeing (Choudhury and Asan 2020).
19.4.4 Dealing withDifcult Medical Problems
When it comes to solving challenging medical issues, articial intelligence (AI) has
a particularly big impact on medication discovery and development. These difculties are frequently caused by the complexity, scarcity, or resistance to traditional
therapies connected to specic illnesses. AI’s revolutionary potential helps create
new strategies and accelerate resolutions for these difcult medical problems. AI
analytics thrives in the eld of complicated diseases by interpreting complex biological data. This makes it possible to identify particular molecular targets, which is
an essential rst step in creating more accurate and potent treatments that are suited
to the complexity of these disorders (Yang et al. 2019). AI is proving to be a
430
https://t.me/med1917
R. Debnath et al.
valuable tool in drug creation, especially for uncommon disorders with few available treatments. Accelerating drug design procedures satises a pressing need and
offers possible benets. The practice of drug repurposing, which looks for novel
answers to challenging medical issues, is one notable example of AI’s impact.
Articial intelligence (AI) provides novel approaches for treatment development by
evaluating pre-existing datasets to nd promising drug candidates for novel therapeutic indications. This strategy offers innovative applications for difcult conditions while optimising the effectiveness of currently available drugs (Fröhlich
etal. 2018).
The use of AI in patient stratication for complex diseases is critical. Personalised
therapies are made possible by the use of machine learning algorithms to identify
specic populations that respond differently to different treatments. This method
ensures individualised therapy based on the unique qualities of each patient,
acknowledging the diversity of patients dealing with challenging medical issues
(Pun etal. 2023).
AI-powered analysis of varied omics data greatly aids in the development of
biomarkers, an essential component of early diagnosis and focused therapies. The
ability to quickly identify biomarkers linked to difcult medical diseases improves
diagnostic capacity and aids in the creation of focused therapies. Another area
where AI helps overcome obstacles related to illnesses that are difcult to cure is
clinical trial optimisation. AI increases the likelihood of successfully discovering
cures for diseases that typically present formidable obstacles by optimising trial
designs. AI systems, which learn from actual patient data, are inherently capable of
continuous learning and adaptability. Because of its exibility, treatment plans can
be continuously improved, guaranteeing that methods change in response to new
information and patient feedback. AI-powered surveillance enables real-time monitoring, which is essential in cases of extreme or quickly worsening situations (Kalid
etal. 2018).
Real-time monitoring of patient data makes timely interventions possible, which
is essential when delays might have a major negative inuence on patient outcomes.
AI enables healthcare practitioners to make well-informed decisions by providing
comprehensive insights through the holistic analysis of varied information. By taking into account a variety of factors that can impact complex medical situations, this
integrated approach helps to provide more efcient and individualised patient treatment (Sebastian and Peter 2022).
To sum up, articial intelligence’s revolutionary impact on medication research
and discovery presents fresh promise for solving challenging medical issues. AI
stimulates creativity, expedites drug development, and makes more individualised
and efcient therapies possible for both uncommon and complicated diseases. AI
technologies have the ability to overcome medical obstacles that were previously
intractable, which could lead to better outcomes for those with challenging health
issues [80].
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
431
19.5 Conclusion
19.5.1 Summary ofAI’s Enormous Potential forMedication
Development andDiscovery
An overview of AI’s immense potential for drug discovery and development of an
overview of articial intelligence’s (AI) immense potential for drug research and
discovery, in conclusion, provides a revolutionary vision of the future of health care.
AI has become a transformative force that surpasses conventional methods and
greatly quickens the rate of medication development. With its potentially revolutionary potential, it holds great promise for revolutionising our understanding, discovery, and delivery of drugs. A paradigm shift in the eld of medicine development
has been brought about by AI’s ability to quickly analyse large and complicated
datasets, forecast prospective therapeutic targets, and optimise drug design processes. Combining machine learning with deep learning algorithms makes it easier
to identify medication candidates more accurately and efciently, which accelerates
the process of turning scientic discoveries into practical therapies. Articial intelligence has made major advances in drug repurposing by sifting through massive
databases and nding previously undiscovered relationships between approved
medications and cutting-edge therapeutic indications. This offers a long-term strategy for utilising current drugs to address novel medical problems in addition to
shortening the development timeframe. As AI makes it possible to identify biomarkers and classify patient populations, patient-centric care becomes increasingly
important. With this individualised approach, treatments will be catered to the
unique qualities of each patient, maximising effectiveness and reducing side effects.
AI’s inuence on clinical trial design also improves efciency, ensuring that patients
receive promising treatment candidates sooner. Articial intelligence systems
exhibit perpetual learning and adaptability that facilitate instantaneous monitoring
and intervention. Not only does this exibility guarantee patient security, but it also
makes continuous therapy advancements possible.
19.5.2 Opening theDoor toaNew Age ofIndividualised Care
Articial intelligence (AI) represents a signicant turning point in the new medication discovery process, ushering in a period of extraordinary progress in the healthcare system and ushering in a phase of tailored treatment. Drug development is
changing, and an era when therapies are customised to meet the specic needs of
each patient is beginning, thanks to the revolutionary junction of cutting-edge technology and medical science. With the introduction of AI, the one-size-ts-all
432
https://t.me/med1917
R. Debnath et al.
methodology of drug discovery has given way to a more individualised strategy,
marking a paradigm change. Articial intelligence’s capacity to evaluate large and
complex datasets makes it possible to gain a better knowledge of the unique traits of
each patient, which opens the door to tailored treatments based on genetic, biochemical, and lifestyle factors. The foundation of AI in health care is made up of
machine learning and deep learning algorithms, which are essential for understanding the intricacies of illnesses. These algorithms are capable of quickly sorting
through massive databases, identifying possible therapeutic targets and improving
the structure of new molecules. Drug discovery proceeds at a faster rate as a result,
advancing the development of effective medications that are also adapted to the
complex molecular underpinnings of various diseases.
Ultimately, the use of AI in the drug discovery process creates new opportunities
for the healthcare industry. That is a signicant turning point that ushers in a new era
of personalised health care, when patients receive therapies that are not only more
customised to their specic needs but also more successful. With AI technology
developing further, there is a chance that personalised medicine will lead to groundbreaking discoveries that could revolutionise the global healthcare system.
References
Abbasi K, Razzaghi P, Poso A, Ghanbari-Ara S, Masoudi-Nejad A (2021) Deep learning in drug tar-
get interaction prediction: current and future perspectives. Curr Med Chem 28(11):2100–2113
Ahmed Z, Mohamed K, Zeeshan S, Dong X (2020) Articial intelligence with multi-functional
machine learning platform development for better healthcare and precision medicine. Database
2020:baaa010
Ahmed F, Soomro AM, Salih AR, Samantasinghar A, Asif A, Kang IS, Choi KH (2022) A compre-
hensive review of articial intelligence and network based approaches to drug repurposing in
Covid-19. Biomed Pharmacother 153:113350
Alanazi A (2023) Clinicians’ views on using articial intelligence in healthcare: opportunities,
challenges, and beyond. Cureus 15(9):e45255
Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, Aldairem A,
Alrashed M, Bin Saleh K, Badreldin HA, Al Yami MS (2023) Revolutionizing healthcare: the
role of articial intelligence in clinical practice. BMC Med Educ 23(1):689
Al-Taie Z, Liu D, Mitchem JB, Papageorgiou C, Kai JT, Warren WC, Shyu CR (2021) Explainable
articial intelligence in high-throughput drug repositioning for subgroup stratications with
interventionable potential. J Biomed Inform 118:103792
Ashri R (2019) The AI-powered workplace: how articial intelligence, data, and messaging plat-
forms are dening the future of work. Apress
Bates DW, Auerbach A, Schulam P, Wright A, Saria S (2020) Reporting and implement-
ing interventions involving machine learning and articial intelligence. Ann Intern Med
172(11_Supplement):S137–S144
Baviskar D, Ahirrao S, Potdar V, Kotecha K (2021) Efcient automated processing of the unstruc-
tured documents using articial intelligence: a systematic literature review and future direc-
tions. IEEE Access 9:72894–72936
Benzidia S, Makaoui N, Bentahar O (2021) The impact of big data analytics and articial intel-
ligence on green supply chain process integration and hospital environmental performance.
Technol Forecast Soc Chang 165:120557
Соседние файлы в папке Библиотека им академика М.И. Перельмана